| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
85,714 |
171,399 |
296,953 |
6,004,552 |
| Total Sell Value |
$820,809 |
$1,715,710 |
$4,867,158 |
$153,876,604 |
| Total People Sold |
4 |
6 |
8 |
11 |
| Total Sell Transactions |
4 |
11 |
16 |
122 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pang Phillip |
Chief Medical Officer |
• – – |
2020-06-03 |
4 |
OE |
$5.18 |
$64,688 |
D/D |
12,500 |
28,277 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2020-06-01 |
4 |
AS |
$35.22 |
$2,641,410 |
D/D |
(75,000) |
222,222 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2020-06-01 |
4 |
OE |
$1.49 |
$111,375 |
D/D |
75,000 |
297,222 |
|
- |
|
| Horn Howard |
CFO |
• – – |
2020-06-01 |
4 |
AS |
$34.53 |
$351,038 |
D/D |
(10,000) |
267,777 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-05-26 |
4 |
AS |
$34.08 |
$129,674 |
D/D |
(3,805) |
0 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-05-26 |
4 |
OE |
$1.53 |
$5,822 |
D/D |
3,805 |
3,805 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-05-18 |
4 |
AS |
$38.00 |
$66,690 |
D/D |
(1,755) |
0 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-05-18 |
4 |
OE |
$1.53 |
$2,685 |
D/D |
1,755 |
1,755 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-05-14 |
4 |
AS |
$30.07 |
$114,418 |
D/D |
(3,805) |
0 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-05-14 |
4 |
OE |
$1.53 |
$5,822 |
D/D |
3,805 |
3,805 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2020-05-14 |
4 |
AS |
$30.05 |
$2,253,885 |
D/D |
(75,000) |
222,222 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2020-05-14 |
4 |
OE |
$1.49 |
$111,375 |
D/D |
75,000 |
297,222 |
|
- |
|
| More Robert J |
Director |
– • – |
2020-05-01 |
4 |
S |
$27.90 |
$516,853 |
D/D |
(18,458) |
71,534 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2020-04-17 |
4 |
OE |
$0.86 |
$6,840 |
D/D |
8,000 |
15,777 |
|
- |
|
| Scangos George A |
President and CEO |
• • – |
2020-04-14 |
4 |
A |
$29.56 |
$6,999,985 |
D/D |
236,806 |
4,713,559 |
|
- |
|
| Scangos George A |
President and CEO |
• • – |
2020-04-14 |
4 |
D |
$29.56 |
$6,999,985 |
I/I |
(236,806) |
1,907,329 |
|
- |
|
| Quinn Christopher |
Former 10% Holder |
– – – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,666,666 |
1,666,666 |
|
- |
|
| V-Sciences Investments Pte Ltd |
10% Owner |
– – • |
2019-10-16 |
4 |
B |
$20.00 |
$10,000,000 |
I/I |
500,000 |
5,499,999 |
1.5 |
- |
|
| V-Sciences Investments Pte Ltd |
10% Owner |
– – • |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
4,999,999 |
4,999,999 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2019-10-16 |
4 |
B |
$20.00 |
$20,000,000 |
I/I |
1,000,000 |
1,000,000 |
2.25 |
- |
|
| Nelsen Robert |
Director |
– • • |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
27,222,219 |
15,555,554 |
|
- |
|
| Frueh Klaus |
Director |
– • – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
218,400 |
362,844 |
|
- |
|
| Burow Kristina |
Director |
– • – |
2019-10-16 |
4 |
B |
$20.00 |
$20,000,000 |
I/I |
1,000,000 |
1,000,000 |
2.1 |
- |
|
| Burow Kristina |
Director |
– • – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
27,222,219 |
15,555,554 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
133,332 |
44,444 |
|
- |
|
575 Records found
|
|
Page 22 of 23 |
|
|
